Giant Lilly, wani kamfani na Amurka, da Novo Nordisk, wani kamfanin Danish, sun yi nasarar sanar da bayanan tallace-tallace na manyan samfuran su a cikin 2020: Dulaglutide ya zama maganin TOP1 GLP-1, tare da tallace-tallace na $ 5.07Bn a cikin 2020, shekara- karuwa a cikin shekara ta 22.8%;Liraglutide Farkon shiga cikin tsaka mai wuya, tallace-tallace a cikin 2020 ya ragu daga $4.14Bn zuwa $3.93Bn, raguwar shekara-shekara na 5.1%;semaglutide ya girma cikin sauri, tare da tallace-tallace ya kai dala biliyan 3.72 a cikin 2020, karuwar shekara-shekara na 119.9%.
Lilly's dulaglutide (sunan kasuwanci Trulicity®) an ƙaddamar da shi a cikin 2014 kuma ya zama maganin toshewa tare da tallace-tallace na $ 5.07Bn a cikin shekaru 6 kacal, ya zama zakaran siyar da magungunan GLP-1.Samfurin guda ɗaya na Novo Nordisk ya koma bayan Lilly na ɗan lokaci.Liraglutide (sunan kasuwanci Victoza® da Saxenda®), wanda aka ƙaddamar a cikin 2009, ya taɓa kasancewa zakaran siyar da magungunan GLP-1, kuma mafi girman tallace-tallace a cikin 2017 ya kai dala biliyan 4.37, kodayake akwai alamomi guda biyu na nau'in ciwon sukari na II da kiba. , bayanai na 2020 sun nuna cewa kasuwa na wannan magani ya shiga lokacin raguwa.Haka Novo Nordisk's semaglutide (sunayen kasuwanci Ozempic® da Rybelsus®) ya girma cikin sauri kuma ya girma zuwa wani maganin blockbuster tare da tallace-tallace na $ 3.72Bn a cikin shekaru uku.Magungunan yana da nau'ikan nau'ikan allura guda biyu na allura da shirye-shiryen baka.
Daga hangen nesa, Amurka ita ce babbar ƙasar tallace-tallace ta liraglutide, tana lissafin kusan 60% a cikin 2020, raguwar shekara-shekara na 11.02%;Hakanan koma bayan tattalin arziki a Amurka ne ya haifar da koma baya a kasuwannin duniya na liraglutide.Yankin EMEA (Turai, Gabas ta Tsakiya, Afirka) ya haɓaka sannu a hankali, tare da CAGR na 1.6% kawai a cikin shekaru biyar da suka gabata;Kasar Sin ita ce kasuwa mafi girma cikin sauri, tare da tallace-tallace na $ 182.50Mn a cikin 2020, tare da haɓaka haɓakar shekara-shekara na 42.39%.Tun da semaglutide ya kasance kan kasuwa ba da daɗewa ba, duk kasuwanni suna cikin wani mataki na haɓaka cikin sauri.Har yanzu Amurka ita ce kasuwa mafi girma, tana lissafin kashi 80.04% na tallace-tallace a cikin 2020, karuwar shekara-shekara na 106.08%;EMEA yana da kashi 13.64% kawai amma adadin girma na shekara-shekara na 249.65% %.An ƙaddamar da Semaglutide a China a cikin 2020 tare da siyar da $ 1.61Mn.Hoto na 3 yana nuna yanayin yanki na dulaglutide.A matsayin babbar kasuwa, Amurka tana da tallace-tallace da ya kai dala biliyan 3.836, wanda ya kai kashi 75.69%, tare da haɓakar haɓakar shekara-shekara na 79.18%.
Babban ikon mallakar liraglutide (Victoza® da Saxenda®) sun ƙare a China kuma suna gab da ƙarewa a cikin Amurka, Japan da Jamus.Yaƙi na Teva tare da Novo Nordisk an daidaita, kuma nau'in nau'in Teva zai kasance a cikin 2023. Mylan kuma ya shigar da aikace-aikacen ANDA tare da FDA don liraglutide tare da da'awar PIV.Tare da ƙarewar sannu a hankali na ainihin haƙƙin mallaka da kuma barazanar masana'antun magungunan ƙwayoyi, miyagun ƙwayoyi za su shiga cikin lokaci na raguwa a hankali.Alamar fili ta Amurka ta Trulicity® ba za ta ƙare ba har sai 2027, yayin da haƙƙin mallaka na manyan ƙasashen Turai da Japan ba za su ƙare ba har sai 2029, kuma ainihin kariyar haƙƙin mallaka ya fi na liraglutide tsayi.Babban ikon mallakar semaglutide (Ozempic® da Rybelsus®) zai ƙare a cikin 2032 a ƙarshe, kuma har yanzu akwai babban ɗaki don haɓaka kasuwa, amma lokacin ƙarewarsa a China shine 2026.
Lokacin aikawa: Yuli-25-2022